Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Interest Expenses (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Interest Expenses for 9 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses rose 12.63% year-over-year to $12.6 million, compared with a TTM value of $45.8 million through Dec 2025, up 22.52%, and an annual FY2025 reading of $45.8 million, up 22.52% over the prior year.
  • Interest Expenses was $12.6 million for Q4 2025 at Karyopharm Therapeutics, up from $11.0 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $12.6 million in Q4 2025 and bottomed at $5.0 million in Q2 2021.
  • Average Interest Expenses over 5 years is $7.9 million, with a median of $6.5 million recorded in 2022.
  • The sharpest move saw Interest Expenses decreased 26.0% in 2021, then soared 87.47% in 2024.
  • Year by year, Interest Expenses stood at $7.9 million in 2021, then dropped by 25.88% to $5.9 million in 2022, then grew by 5.49% to $6.2 million in 2023, then soared by 80.48% to $11.2 million in 2024, then increased by 12.63% to $12.6 million in 2025.
  • Business Quant data shows Interest Expenses for KPTI at $12.6 million in Q4 2025, $11.0 million in Q3 2025, and $11.2 million in Q2 2025.